Johnson & Johnson JNJ MEDTECH — Goodwill (Note 3)
Other segment segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Johnson & Johnson in its filing.
Tagged under the XBRL concept us-gaap:Goodwill.
The official record: Johnson & Johnson’s 10-Q, filed April 22, 2026, on SEC EDGAR. View the filing →
Ask your AI about Johnson & Johnson's medtech — goodwill (note 3).
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Johnson & Johnson's MEDTECH — goodwill (note 3)?
- Johnson & Johnson (JNJ) reported MEDTECH — goodwill (note 3) of $33.75B in Q1 2026.
- How has Johnson & Johnson's MEDTECH — goodwill (note 3) changed year-over-year?
- Johnson & Johnson's MEDTECH — goodwill (note 3) increased by 0.6% year-over-year, from $33.56B to $33.75B.
- What is the long-term trend for Johnson & Johnson's MEDTECH — goodwill (note 3)?
- Over 4 years (2021 to 2025), Johnson & Johnson's MEDTECH — goodwill (note 3) has grown at a 22.7% compound annual growth rate (CAGR), from $59.56B to $134.94B.
- What does MEDTECH — goodwill (note 3) mean?
- Represents the total carrying value of goodwill allocated to the MedTech operating segment as reported in the financial notes. This reflects the premium paid over the fair value of identifiable net assets during historical acquisitions within the medical device business.